
GlaxoSmithKline plc GSK
$ 50.53
0.3%
Annual report 2025
added 04-18-2026
GlaxoSmithKline plc ROCE Ratio 2011-2026 | GSK
Annual ROCE Ratio GlaxoSmithKline plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 13.35 | -36.78 | -19.42 | -17.9 | 7.72 | 3.93 | 7.98 | 10.59 | 11.15 | 12.87 |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.35 | -36.78 | -0.65 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | ||
|
Exelixis
EXEL
|
40.35 | $ 48.7 | 9.64 % | $ 13.2 B | ||
|
Fortress Biotech
FBIO
|
-140.8 | $ 2.55 | 3.66 % | $ 71.1 M | ||
|
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | ||
|
Galapagos NV
GLPG
|
-3.51 | $ 28.81 | 1.48 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
31.74 | $ 27.89 | 1.28 % | $ 17.2 B | ||
|
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | ||
|
Genprex
GNPX
|
-194.87 | $ 0.89 | 0.58 % | $ 830 K | ||
|
Grifols, S.A.
GRFS
|
7.15 | $ 8.41 | 1.69 % | $ 6.83 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | ||
|
InflaRx N.V.
IFRX
|
-24.77 | $ 2.5 | 26.9 % | $ 152 M | ||
|
Ionis Pharmaceuticals
IONS
|
-43.85 | $ 76.85 | 2.13 % | $ 12.3 B | ||
|
Kamada Ltd.
KMDA
|
10.36 | $ 8.28 | 0.85 % | $ 260 M | ||
|
Kymera Therapeutics
KYMR
|
-22.12 | $ 86.26 | 4.29 % | $ 7.29 B | ||
|
BioNTech SE
BNTX
|
-4.81 | $ 95.26 | -0.25 % | $ 27.2 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-2.72 | $ 232.55 | 0.11 % | $ 4.25 B | ||
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | ||
|
Liquidia Corporation
LQDA
|
-114.81 | $ 42.14 | 5.01 % | $ 3.63 B | ||
|
INmune Bio
INMB
|
-201.42 | $ 1.52 | -1.3 % | $ 37.6 M | ||
|
Mirum Pharmaceuticals
MIRM
|
-7.03 | $ 110.08 | 4.04 % | $ 5.53 B | ||
|
MannKind Corporation
MNKD
|
-76.05 | $ 3.56 | 24.48 % | $ 1.09 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 21.48 | -3.89 % | $ 3.56 B | ||
|
Nanobiotix S.A.
NBTX
|
-31.68 | $ 41.86 | 20.39 % | $ 286 B | ||
|
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.15 | 1.19 % | $ 655 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.35 | -4.29 % | $ 5.51 M | ||
|
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | ||
|
Puma Biotechnology
PBYI
|
28.62 | $ 7.45 | 1.36 % | $ 373 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.17 | 3.2 % | $ 3.08 B | ||
|
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | ||
|
Pfizer
PFE
|
10.69 | $ 26.53 | 0.3 % | $ 151 B |